Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cogstate Ltd ( (AU:CGS) ) has provided an update.
Cogstate Limited has announced a change in the director’s interest, with Bradley O’Connor acquiring an additional 50,327 ordinary shares on the market at $1.738 per share, valued at $87,485. This acquisition reflects a strategic move that may impact the company’s market perception and stakeholder confidence, as it indicates potential growth or confidence in the company’s future performance.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.19 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Limited operates in the healthcare industry, specializing in cognitive assessment and brain health solutions. The company provides products and services that support clinical trials, academic research, and healthcare providers in assessing cognitive function.
YTD Price Performance: 65.54%
Average Trading Volume: 85,847
Technical Sentiment Signal: Buy
Current Market Cap: A$290.8M
Learn more about CGS stock on TipRanks’ Stock Analysis page.